The Genomic Prostate Score Can Help to Personalize Your Course of Care
The result of the Oncotype DX prostate cancer test is provided as a Genomic Prostate Score (GPS).Your GPS is a measure of the activity of certain genes within your tumor, and can help to predict the aggressiveness of your prostate cancer. Used along with other clinical risk factors, your GPS can be used to personalize your prostate cancer treatment based on the underlying biology of your tumor.
The GPS works in combination with risk assessment based on guidelines set by the NCCN®1 (National Comprehensive Cancer Network). According to these guidelines, your doctor will determine if your prostate cancer is considered very low risk, low risk, or intermediate risk. If your prostate cancer is considered high risk, then you are not a candidate for the Oncotype DX test.
The additional information provided by your GPS will either confirm that you are in the correct risk group and where you are in that risk group, or will indicate whether your cancer is more favorable than or less favorable than your original risk group. Within that clinical risk group, the lower your GPS, the less likely it is that you will need invasive treatment for your prostate cancer. The higher your GPS, the more likely your doctor will recommend immediate treatment such as surgery or radiation therapy.
1 NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer, Version 3.2012. NCCN is a registered trademark of the National Comprehensive Cancer Network, which does not endorse any product or therapy.
Your GPS gives you and your doctor greater confidence when choosing your course of care.